Remarkably, among the patients with ER-positive, HER2-positive breast cancer, those with low ER expression or high HER2 expression alongside elevated TIL levels exhibited response rates comparable to patients with ER-negative, HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.